GLP-1 (7-37) Acetate
Sequentia: His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly
alias : 7-37-Glucagon-likepeptide I (humano);Glucagon-relatedpeptide 1 (Rana catesbeiana),3-L-glutamicacid-10-L-valine-16-glycinum-17-L-glutaminum-23-L-isoleucinum-24-L-alanine-27-L-valine-31-glycinum 32-de-L-lysinum.-
Cas No.: 106612-94-6
Formulae hypotheticae: C151H228N40O47
M. Pondus: 3355.74
Puritas (HPLC): 99.0%
Aspectus: Pulvis albus
una immunditia (HPLC): 1.0%
Amino Acidum Compositio: 10% theoretical
Peptide Content (N%): 80% (by %N)
Aqua Content (Carolus Fischer): 6.0%
Acetate Content (HPIC): 15.0%
Gradus : Pharmaceutical Grade
Repono: Clausa, infra 2 ~ 8℃ preservation
Usage : GLP-1 can obviously improve the blood glucose in type 2 diabetes animal models or patients through a variety of mechanisms, which promote the regeneration and repair of islet beta cells, increase the number of beta cells is particularly significant role, provides a very good prospect for the treatment of type 2 diabete mellitus.
Glucagon-like peptide-1 (GLP-1) is derived from the transcription product of the proglucagon gene. The major source of GLP-1 in the body is the intestinal L cell that secretes GLP-1 as a gut hormone. The biologically active forms of GLP-1 are:GLP-1-(7-37) and GLP-1-(7-36)NH2.
GLP-1 secretion by L cells is dependent on the presence of nutrients in the lumen of the small intestine. The secretagogues (agents that cause or stimulate secretion) of this hormone include major nutrients like carbohydrate, protein and lipid. Once in the circulation, GLP-1 has a half life of less than 2 minuta, due to rapid degradation by the enzyme dipeptidyl peptidase-4.
GLP-1 (7-37) is a truncated, bioactive form of GLP-1 that is the product of proglucagon processing in intestinal endocrine L cells. It is a potent insulinotropic hormone.
Effect of GLP-1 GLP-1 can protect beta cells can act on the pancreatic beta cells, promote the synthesis of insulin, insulin gene transcription and secretion and can stimulate the proliferation and differentiation of islet beta cells, inhibit the apoptosis of pancreatic beta cells, increase the number of beta cell of islet [2-5]. Insuper, GLP-1 also can be applied to the pancreatic alpha cells, fortiter prohibere emissione glucagon, et agunt in insula Delta cellae, promovere secretionem somatostatin, cellulae somatostatinae adhiberi possunt ut hormona paracrina, quae in inhibitione glucagoni implicatur.
GLP-1 concentratio glucosa cum effectu hypoglycemico dependens, i.e. tantum oriri in gradus GLYCOSA sub conditione GLP-1, tantum ludere a hypoglycemic effectus, sed normalis sanguis sugar campester ", nihil minui fecit. GLYCOSA concentratio dependentiae GLP-1 est eius proprietatibus hypoglycemicis clinicis applicationis salus fundationis et securitatis., ita vitandi homines possunt gravi hypoglycemia in aegris cum existentium medicamento curatio diabete et ratio anxietatis.
